이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

AVL-102 for the Treatment of HPV 16/18/52/58-Related High-Grade Lesions

2026년 11월 11일 업데이트: Beijing Xunsheng Biomedical Research Co., Ltd.

Phase Ia Clinical Trial Evaluating the Safety, Tolerability, and Primary Efficacy of AVL-102 in Patients With High-grade Intraepithelial Lesions Associated With Untreated HPV16/18/52/58 Infection.

This study was designed to evaluate the safety, tolerability, and efficacy of AVL-102 Injection in the treatment of high-grade cervical intraepithelial neoplasia (CIN2/3) caused by HPV 16/18/52/58 infection.

연구 개요

상태

모병

연구 유형

중재적

등록 (추정된)

12

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Beijing Municipality
      • Xicheng, Beijing Municipality, 중국, 100044
        • 모병
        • Peking University People's Hospital
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

여성

설명

Inclusion Criteria:

  1. Women aged 18-64 (inclusive) .
  2. Participants voluntarily joined the study and signed informed consent forms.
  3. During the screening period, if there are no clinically significant abnormalities in medical history, physical examination, vital signs, 12-lead electrocardiogram, and clinical laboratory test results, the researchers will determine that the candidate is suitable for enrollment .
  4. Patients whose screening pathology results confirm HPV types 16 and/or 18 and/or 52 and/or 58 (with or without non-high-risk subtypes, excluding high-risk subtypes 31, 33, 35, 39, 45, 51, 56, 59, 66, 68), evidence of cervical intraepithelial lesion CIN2/3, and who have not received standard treatment.
  5. Eligible trial participants of childbearing age (defined as women who have not undergone hysterectomy, bilateral salpingectomy, or bilateral oophorectomy and have not been menopausal for ≥12 months) must agree to use highly effective contraception (such as oral contraceptives, intrauterine devices, barrier contraception combined with spermicide, or partner sterilization) with their partners during the study treatment period and for at least 12 months after the last dose.
  6. During the screening period, trial participants were not pregnant or breastfeeding and were willing to undergo additional pregnancy testing as required throughout the trial.
  7. Willing and able to comply with and complete all research procedures.

Exclusion criteria:

  1. Any skin condition on the upper arm that may interfere with the assessment of injection site reaction (ISR), including but not limited to large tattoos, scars, rashes, infections, or wounds.
  2. There was a severe venous defect, making it impossible to collect the blood sample required by the protocol.
  3. The screening criteria included acute infections of the genital tract or anus requiring systemic anti-infective treatment (excluding HPV infection).
  4. Those who are pregnant or breastfeeding, or who have a history of miscarriage within 3 months prior to screening.
  5. Medical conditions that, in the researchers' judgment, would increase the risk of bleeding during a biopsy.
  6. In addition to the study indication, patients with any clinically significant acute or chronic disease that, in the investigator's opinion, may increase the risk of exposure to the investigational drug or interfere with the study evaluation.
  7. Individuals who are not suitable for a full colposcopy evaluation.
  8. Any of the following situations exist:

1)The pathology of the target lesion during the screening period confirmed adenocarcinoma, adenocarcinoma in situ (AIS), or invasive carcinoma; 2)of the cervix , vagina , vulva , or anus ; 3)During the screening period, microscopic examination revealed a suspected malignant tumor .

4)Having undergone a total hysterectomy and therefore unable to assess cervical lesions ; 5)excluding cured papillary thyroid carcinoma, basal cell carcinoma of the skin, cervical carcinoma in situ, etc. ) in locations other than those mentioned above within the 5 years prior to enrollment .

9.Immunosuppressants used continuously (for more than 7 days ) within 30 days prior to screening , including but not limited to: Glucocorticoids (excluding physiological replacement doses: prednisone ≤10 mg/d or other glucocorticoids at equivalent doses); cyclosporine, tacrolimus, azathioprine, 6-mercaptopurine, methotrexate, etc.

10.Those who have received a known anti-HPV drug (including HPV prophylactic vaccine) within 30 days prior to screening.

11.Those who have previously undergone surgery or physical therapy for high-grade intraepithelial lesions, including but not limited to: loop electrosurgical excision procedure (LEEP), cold knife conization (CKC), laser ablation/resection, cryotherapy, electrocautery, photodynamic therapy, microwave therapy, focused ultrasound therapy, and other invasive/minimally invasive resection or ablation treatments targeting the lesion tissue.

12.A history of severe allergies (requiring hospitalization), a severe reaction to any medication or vaccine injection, or any known or suspected allergy to any component of an investigational drug or preparation.

13.Individuals with uncontrolled systemic chronic diseases. 14.The screening period laboratory tests meet any of the following criteria:

  1. Hemoglobin < 90 g/L;
  2. Neutrophil count < 1.0 × 10⁹ /L;
  3. Platelet count < 80 × 10⁹ /L;
  4. AST or ALT > 1.5×ULN;
  5. Creatinine clearance < 60 mL/min (Cockcroft-Gault formula);
  6. International Normalized Ratio (INR) > 1.5 × ULN;
  7. Positive for HIV antibodies;
  8. HCV antibody positive (and HCV RNA positive);
  9. HBsAg positive (and HBV DNA positive);
  10. Active syphilis (RPR/TPPA positive and requiring treatment). 15.Researchers believe there may be a history of alcohol or drug abuse that could affect the safety or compliance of trial participants .

16.Researchers consider participants who are unwilling or unable to comply with the requirements of the research protocol to be experimental participants.

Alternative criteria for trial participants :

To ensure the scientific validity and reliability of the experimental data, supplementary trials may be conducted by recruiting new participants if the following situations occur during the research process :

  1. If the researchers determine that there are other circumstances that make it unsuitable to continue AVL-102 injection before the injection, the participant will withdraw from the study, and a replacement participant may be selected through a new screening process.
  2. If a participant fails to complete three doses of AVL-102 injection or withdraws for any reason (excluding DLT reasons) and thus fails to complete the DLT assessment, a replacement participant can be selected through a new screening process.

Exit criteria:

Participants have the right to voluntarily withdraw from the study treatment at any time. Furthermore, the investigator may decide to withdraw a participant from the study treatment if the participant meets the following withdrawal criteria :

  1. DLT occurs;
  2. In cases where an adverse event (AE) or a serious adverse event (SAE) occurs, and the investigator determines that it is necessary to withdraw from the study;
  3. Participants in the trial had pre-existing high-grade intraepithelial lesions that progressed or became cancerous;
  4. The trial participants had poor compliance and were unable to participate in the treatment, visits, and follow-ups specified in the study, or were lost to follow-up.
  5. The trial participants insisted on withdrawing their informed consent and requested to withdraw from the trial;
  6. Other situations where researchers deem it inappropriate for participants to continue in the trial.

For each trial participant who discontinues study treatment , the investigator must record all required details in the electronic case report form (eCRF), including the date and reason for treatment discontinuation. Before withdrawing from the study, trial participants who discontinue study treatment must complete all examinations required for the final visit as specified in the trial protocol and undergo the corresponding follow-up. For all trial participants who withdraw from the study due to adverse events , follow-up must be conducted until the event is resolved, stabilized, returns to baseline levels, is attributable to a cause other than the study drug, or if further information is unavailable. The results must be recorded in the eCRF (and, after database locking, the follow-up results should be recorded in the original files at the research institution).

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: AVL-102 Q3W×3

A total of 3 injections of AVL-102 are to be administered, with an interval of three weeks between each. The drug is to be given via intramuscular injection into the lateral aspect of the upper arm, 2-3 finger-widths below the acromion; each dose should be administered into one of the upper arms. Following each injection, the recipient must remain under observation for 60 minutes, during which time a safety assessment will be conducted.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
기간
Dose-limiting toxicities (DLT),incidence and severity of adverse events, etc.
기간: Up to day 300
Up to day 300
Maximum tolerated dose (MTD) and RDE
기간: Up to day 300
Up to day 300

2차 결과 측정

결과 측정
측정값 설명
기간
Geometric Mean Titer (GMT) of Anti-HPV16/18/52/58 Antigen-Specific Antibodies
기간: Up to day 300

Humoral immune response evaluated by measuring serum antigen-specific antibody titers against HPV types 16, 18, 52, and 58 using Enzyme-Linked Immunosorbent Assay (ELISA).

Up to day 300
Cell-Mediated Specific Immune Response Against HPV16/18/52/58 Antigens
기간: Up to Day 300

Cellular immune response evaluated by measuring the number of IFN-γ secreting antigen-specific T cells per million peripheral blood mononuclear cells (PBMCs) using Enzyme-Linked Immunospot (ELISpot) assay, reported as Spot Forming Cells (SFCs)/10^6 PBMCs.

Up to Day 300
Validity
기간: Up to day 300
  1. The extent of lesion regression as assessed by histopathology at the last visit ;
  2. The rate of HPV16/18/52/58 single or multiple virus positivity turning negative at the last visit .
Up to day 300

기타 결과 측정

결과 측정
측정값 설명
기간
Exploratory endpoint indicators-Pharmacokinetics-Maximum Observed Plasma Concentration (Cmax)
기간: Up to day 43

Peak plasma concentration of the study drug measured after administration (Unit: ng/mL)

Up to day 43
Exploratory endpoint indicators-Pharmacokinetics-Time to Reach Maximum Observed Plasma Concentration (Tmax)
기간: Up to day 43

Time elapsed from drug administration to reach Cmax (Unit: hours).

Up to day 43
Exploratory endpoint indicators-Pharmacokinetics-Area Under the Plasma Concentration-Time Curve from Time Zero to the Last Quantifiable Concentration (AUC0-t)
기간: Up to day 43

Calculated using the linear trapezoidal method from time 0 to the last measurable concentration time point (Unit: h*ng/mL).

Up to day 43
Exploratory endpoint indicators-Pharmacokinetics-Area Under the Plasma Concentration-Time Curve from Time Zero Extrapolated to Infinity (AUC0-∞)
기간: Up to Day 43

Calculated as AUC0-t plus the extrapolated area from the last measurable concentration to infinity (Unit: h*ng/mL).

Up to Day 43
Exploratory endpoint indicators-Pharmacokinetics-Terminal Elimination Half-Life (t1/2)
기간: Up to Day 43

Time required for the plasma concentration of the drug to decrease by 50% during the terminal elimination phase (Unit: hours).

Up to Day 43
Exploratory endpoint indicators-Pharmacokinetics-Mean Residence Time (MRT)
기간: Up to Day 43

Average time the drug molecules stay in the body after administration (Unit: hours).

Up to Day 43
Exploratory endpoint indicators-Pharmacokinetics-Total Plasma Clearance (CL)
기간: Up to Day 43

Volume of plasma from which the drug is completely removed per unit time (Unit: L/h).

Up to Day 43
Exploratory endpoint indicators-Pharmacokinetics-Terminal Elimination Rate Constant (λz)
기간: Up to Day 43

First-order rate constant associated with the terminal (log-linear) portion of the concentration-time curve (Unit: 1/h).

Up to Day 43
Exploratory endpoint indicators-Pharmacokinetics-Apparent Volume of Distribution (Vd)
기간: Up to Day 43

Theoretical volume that would be necessary to contain the total amount of an administered drug at the same concentration that it is observed in the blood plasma (Unit: L).

Up to Day 43
Exploratory endpoint indicators-Cytokines
기간: Up to day 300

Expression level of IL-1β, IL-2, IL-6, IL-10, GM-CSF, TNF-α and IFN-γ

Up to day 300
Exploratory endpoint indicators-PEG antibody
기간: Up to day 126

Anti-polyethylene glycol (PEG) antibody response: Serum anti-PEG IgG and anti-PEG IgM titers were measured by enzyme-linked immunosorbent assay (ELISA) to assess the potential association between the immunogenicity of the PEGylated lipid components in LNP and its adverse reactions after repeated administration.

Up to day 126

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 9월 23일

기본 완료 (추정된)

2027년 7월 31일

연구 완료 (추정된)

2028년 4월 30일

연구 등록 날짜

최초 제출

2026년 10월 28일

QC 기준을 충족하는 최초 제출

2026년 11월 11일

처음 게시됨 (실제)

2026년 11월 17일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 17일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 11일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다